3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomatitis
2
Neoplasms
2
Mucositis
2
Vulvodynia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Pain, Postoperative
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
MRSA Colonization
1
Lymphoma
1
Leukemia
1
Ilues
1
Hydronephrosis
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Dyspareunia
1
Disease
1
Interventions
Mitomycin
11
Gemcitabine
7
BCG Vaccine
4
Imiquimod
2
Administration, Intravesical
2
viscum album peptide
1
pemigatinib
1
pembrolizumab
1
erdafitinib
1
dodecyl maltoside
1
Water
1
VPM1002 recombinant BCG vaccine
1
VB4-845
1
Therapeutics
1
Photochemotherapy
1
Neoadjuvant Therapy
1
Interferon-alpha
1
Hyaluronic Acid
1
High-Intensity Interval Training
1
Gels
1
Ethacrynic Acid
1
Epirubicin
1
Educational Status
1
Doxorubicin
1
Docetaxel
1
Dihematoporphyrin Ether
1
Cystoscopy
1
Celecoxib
1
BCG Connaught
1
5-aminolevulinic acid hexyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-Muscle Invasive Bladder Neoplasms
×
Water
×
Clear all
NCT01803295
2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA
Completed
80 enrolled